골형성부전증 치료 시장 : 약물별, 투여 경로별, 지역별

Osteogenesis Imperfecta Treatment Market is estimated to be valued at USD 777.9 Mn in 2026 and is expected to reach USD 931.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.6% from 2026 to 2033.

Osteogenesis imperfect, or OI, is a genetic disorder that affects the bones and also prevents the body from building strong bones. This disease makes the bones brittle and breaks easily without any cause. OI is referred to as imperfect bone formation, and people suffering from this disorder have bones that fracture or break easily. Therefore, this condition is also commonly known as brittle bone disease. In severe OI cases, multiple fractures are common, whereas a milder case involves a few fractures or bone breaks in a person's lifetime. People with this condition are either born unable to produce connective tissue or have it due to faulty genes. It has an impact on the synthesis of collagen, the connective tissue protein that strengthens bones. The illness comes in I and IX forms, with I being mild and IX being fatal. The major sign of osteogenesis imperfecta is frequent fractures. Other symptoms include loose joints, deformed bones, loss of hearing, breathing issues, and tooth problems. Osteogenesis imperfecta can be confirmed through DNA or collagen testing. There is no treatment for it because it is a genetic condition. Exercise and giving up smoking are two examples of healthy lifestyle choices that can help prevent fractures. Braces, painkillers, and correct bone fracture care are all beneficial. Antibiotics and antiseptics can be used to treat bone infections. Rising demand for novel therapies for osteogenesis imperfecta treatment and licensing agreements and strategic collaborations by key industry players for the development of OI treatment are expected to propel the growth of global osteogenesis imperfecta treatment market over the forecast period.

Market Dynamics

The surge in funding for research & development to develop novel treatment and therapies is a major factor boosting growth of the global osteogenesis imperfecta treatment market. Moreover, licensing agreements and strategic collaborations by key industry players for the development of OI treatment is another factor propelling the market growth. Moreover, osteogenesis imperfecta is a genetic disorder and the family history of people with OI is resulting in rising number of cases across the globe, which is expected to drive the market growth. For instance, in May 2021, Mereo BioPharma Group plc announced encouraging 6-month data from its phase II-B clinical study in adult patients with Type IV, III, or I osteogenesis imperfecta treated with setursumab (BPS-804). The European Medicines Agency (EMA) had approved the company's pediatric investigation plan for BPS-804 and with a registration study design, and the drug candidate is now phase III ready for a pediatric population.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global osteogenesis imperfecta treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global osteogenesis imperfecta treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteogenesis imperfecta treatment market

Detailed Segmentation:

• Global Osteogenesis Imperfecta Treatment Market, By Drugs (Revenue, USD Mn, 2021 - 2033)
• Teriparatide
• Denosumab
• Others
• Global Osteogenesis Imperfecta Treatment Market, By Route of Administration:
• Subcutaneous
• Intravenous
• Oral
• Others
• Global Osteogenesis Imperfecta Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• BioSenic SA
• Mereo Biopharma Group PLC
• CELGENE CORPORATION
• Eli Lilly and Company
• Cipla Inc.
• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Jubilant Pharmova Limited
• Aurobindo Pharma
• Quince
• Ultragenyx Pharmaceutical Inc.
• OrthoPediatrics Corp.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drugs
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • New Development in Osteogenesis Imperfecta Treatment
  • Pipeline Analysis
  • Merger, Acquisition, Collaborations
  • Funding and Investment
  • Key Developments
  • PEST Analysis
  • PORTER's Analysis

4. Global Osteogenesis Imperfecta Treatment Market, By Drugs, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Teriparatide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Denosumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

5. Global Osteogenesis Imperfecta Treatment Market, By Route of Administration, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segments Trends
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

6. Global Osteogenesis Imperfecta Treatment Market, By Region, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• BioSenic SA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mereo Biopharma Group PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CELGENE CORPORATION
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Jubilant Pharmova Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aurobindo Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Quince
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ultragenyx Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• OrthoPediatrics Corp.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

8. Section

• Research Methodology
• About Us